Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.

Aman Chandra KaushikYan-Jing WangXiangeng WangDong-Qing Wei

Published in: Briefings in bioinformatics (2021)

KRAS and TP53 prognosis of PAAD is directly associated with a specific mutation of KRAS. Irinotecan and vandetanib are prospective drugs for PAAD patients with KRASG12Dmutation and TP53 mutation.

Keyphrases

wild type
combination therapy
drug induced